Subscribe Login

Acquisitions And Cost-Cutting 'Not Enough' To Boost Reckitt Benckiser: Analysis

By Steve Wynne-Jones
Share this article
Acquisitions And Cost-Cutting 'Not Enough' To Boost Reckitt Benckiser: Analysis

Household and consumer health-care giant Reckitt Benckiser needs to focus less on acquisitions and cost-cutting if it wants to appease shareholders, according to a leading industry analyst.

Following the publication of the Nurofen parent's full-year results earlier today, Russ Mould, investment director at pension, investment and stockbroker firm AJ Bell, said, "A return to sales growth in the fourth quarter, increased cost-saving targets and a higher dividend are not proving enough for shareholders in Reckitt Benckiser, whose shares are the worst performers in the FTSE 100 in early trading."

Reckitt Benckiser posted flat like-for-like revenue (at constant-currency levels) for full-year 2017 (£11.5 billion), with an increase of 2% reported in the final quarter of the year (£3.29 billion).


30 Day Free Trial

Try European Supermarket Magazine Premium

Enjoy full access to European Supermarket Magazine, our weekly
email news digest, access to all website and app content, and the latest digital
magazine for a full 30 days.

  • - Payment details required during trial sign up.
  • - You may cancel at any time up to the end of the 30-day trial period.
  • - If you continue after the trial perion, then the annual rate of €109+VAT will be debited.
Get the week's top grocery retail news

The most important stories from European grocery retail direct to your inbox every Thursday

Processing your request...

Thanks! please check your email to confirm your subscription.

By signing up you are agreeing to our terms & conditions and privacy policy. You can unsubscribe at any time.